Ideas to Action:

Independent research for global prosperity


Global Health Policy Blog


On Monday, the European Medicines Agency approved GSK's Rotarix (see article in the Financial Times). This comes right on the heels of the U.S. Food and Drug Administration's approval of Merck's rival vaccine Rotateq; both offer children protection against diarrheal disease caused by rotavirus, which kills nearly 500,000 children and hospitalizes two million more.

Like Merck before it, GSK has pledged to make their vaccine available and affordable to developing countries, but has not yet completed the necessary clinical trials.

Related Topics:


CGD blog posts reflect the views of the authors, drawing on prior research and experience in their areas of expertise. CGD is a nonpartisan, independent organization and does not take institutional positions.